Sultanate of Oman Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control Muscat



سلطنة عُمان وزارة الصحة المديرية العامة للصيدلة والرقابة الدوائية مسقط

To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

Director General of Royal Hospital

Director General of Khoula Hospital

Director General of Medical Supplies (MOH)

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No 217 dated 23 /10 / 2023 Regarding NCMDR recall of Specific Lots of VENTANA anti-ALK (D5F3) Antibody from (mfr: Roche Diagnostics GmbH).

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information





Sultanate of Oman
Ministry of Health
Directorate General of Pharmaceutical
Affairs and Drug Control
Muscat



سلطنة عُمان وزارة الصحة المديرية العامية للصيدلة والرقابة الدوائية مسقط

Circular No. 217/2023 Oving Forward with Confidence

© \$ -04-1445 H Q 3 -10-2023

Recall of Specific Lots of VENTANA anti-ALK (D5F3) Antibody from Roche Diagnostics GmbH

NCMDR- National Center for Medical Devices Reporting- SFDA
https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&rid=19724
Specific Lots of VENTANA anti-ALK (D5F3) Antibody.
An in vitro diagnostic medical device (IVD).
Roche Diagnostics GmbH.
National Pharmacy LLC.
Product name (part number):
- VENTANA ALK (D5F3) CDx Assay (06687199001 / 790-4796);
- VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (06679072001 / 790-
4794).
Lot numbers: H35641, H36978, J01547, J06534 and J11153
Please refer to the attachment for manufacturing, labeled expiration & 14 month short dates.
It has been observed light staining during routine internal Stability & Surveillance monitoring
by the manufacturer of above products.
 Customers should discontinue use and discard any remaining inventory of lots Mentioned above.
 It is recommended that customers review patient samples tested after the shortened expiry date and retest any clinically diagnosed negative VENTANA anti-ALK (D5F3) results, especially where only appendix is being utilized as a positive tissue control. Contact the local agent for remedial action.
Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: Med-device@moh.gov.om

Dr. Mohammed Hamdan Al Rubaie

Director General





